143 related articles for article (PubMed ID: 12471570)
1. Widespread use of fluoroquinolones versus emerging resistance in pneumococci.
Goldstein EJ; Garabedian-Ruffalo SM
Clin Infect Dis; 2002 Dec; 35(12):1505-11. PubMed ID: 12471570
[TBL] [Abstract][Full Text] [Related]
2. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
Chen DK; McGeer A; de Azavedo JC; Low DE
N Engl J Med; 1999 Jul; 341(4):233-9. PubMed ID: 10413735
[TBL] [Abstract][Full Text] [Related]
3. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
[TBL] [Abstract][Full Text] [Related]
4. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
5. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
[TBL] [Abstract][Full Text] [Related]
6. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
7. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
8. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?
Mandell LA; Peterson LR; Wise R; Hooper D; Low DE; Schaad UB; Klugman KP; Courvalin P
Clin Infect Dis; 2002 Sep; 35(6):721-7. PubMed ID: 12203170
[TBL] [Abstract][Full Text] [Related]
9. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
10. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
Schurek KN; Adam HJ; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294
[TBL] [Abstract][Full Text] [Related]
11. PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan.
Inoue M; Kohno S; Kaku M; Yamaguchi K; Igari J; Yamanaka K
Int J Infect Dis; 2005 Jan; 9(1):27-36. PubMed ID: 15603993
[TBL] [Abstract][Full Text] [Related]
12. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
Farrell DJ; Jenkins SG
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832
[TBL] [Abstract][Full Text] [Related]
13. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2005 Dec; 26(6):575-616. PubMed ID: 16388429
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone AUIC break points and the link to bacterial killing rates: in vitro models.
Zhanel GG; Noreddin AM
Ann Pharmacother; 2003 Sep; 37(9):1331-4. PubMed ID: 12921519
[No Abstract] [Full Text] [Related]
15. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
16. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
Sahm DF; Brown NP; Draghi DC; Evangelista AT; Yee YC; Thornsberry C
Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
18. [Alexander Project--5 years in Poland].
Hryniewicz W
Pol Merkur Lekarski; 2003 Jan; 14(79):5-8. PubMed ID: 12712818
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
[TBL] [Abstract][Full Text] [Related]
20. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
Johnson DM; Stilwell MG; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
